loadpatents
name:-0.034796953201294
name:-0.013957977294922
name:-0.0092208385467529
Bluestone; Jeffrey A. Patent Filings

Bluestone; Jeffrey A.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bluestone; Jeffrey A..The latest application filed is for "car-t cells specific for modified proteins in extracellular spaces".

Company Profile
8.12.31
  • Bluestone; Jeffrey A. - Oakland CA
  • Bluestone; Jeffrey A. - San Francisco CA
  • Bluestone; Jeffrey A. - US
  • Bluestone; Jeffrey A. - Chicago IL
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Car-t Cells Specific For Modified Proteins In Extracellular Spaces
App 20220281943 - Bluestone; Jeffrey A. ;   et al.
2022-09-08
CD127 expression inversely correlates with FoxP3 and suppressive function of CD4.sup.+ Tregs
Grant 11,435,349 - Bluestone , et al. September 6, 2
2022-09-06
Compositions And Methods For Modifying Regulatory T Cells
App 20210340496 - Marson; Alexander ;   et al.
2021-11-04
Compositions And Methods For Modifying Regulatory T Cells
App 20210147841 - Marson; Alexander ;   et al.
2021-05-20
Anti-il-2 Antibodies And Compositions And Uses Thereof
App 20210061902 - RONDON; Isaac J. ;   et al.
2021-03-04
Lfa3 Variants And Compositions And Uses Thereof
App 20210032308 - CRELLIN; Natasha Kay ;   et al.
2021-02-04
Cellular Signaling Domain Engineering In Chimeric Antigen Receptor-modified Regulatory T Cells
App 20210017248 - Bluestone; Jeffrey A. ;   et al.
2021-01-21
Car-t Cells And Autoimmune Diseases
App 20200399355 - BLUESTONE; JEFFREY A. ;   et al.
2020-12-24
Preservation Of Pancreatic Islet Grafts In The Extrahepatic Space
App 20200360446 - WARD; Casey ;   et al.
2020-11-19
Anti-IL-2 antibodies and compositions and uses thereof
Grant 10,738,113 - Rondon , et al. A
2020-08-11
Anti-il-2 Antibodies And Compositions And Uses Thereof
App 20190106488 - Rondon; Isaac J. ;   et al.
2019-04-11
Glycosphingolipids for use in modulating immune responses
Grant 10,227,290 - Fischbach , et al.
2019-03-12
Anti-IL-2 antibodies and compositions and uses thereof
Grant 10,138,298 - Rondon , et al. Nov
2018-11-27
Cd127 Expression Inversely Correlates With Foxp3 And Suppressive Function Of Cd4+ Tregs
App 20180238880 - Bluestone; Jeffrey A. ;   et al.
2018-08-23
CD127 expression inversely correlates with FoxP3 and suppressive function of CD4+ tregs
Grant 9,977,021 - Bluestone , et al. May 22, 2
2018-05-22
Expansion Of Alloantigen-reactive Regulatory T Cells
App 20180036345 - TANG; Qizhi ;   et al.
2018-02-08
Expansion of alloantigen-reactive regulatory T cells
Grant 9,801,911 - Tang , et al. October 31, 2
2017-10-31
Anti-il-2 Antibodies And Compositions And Uses Thereof
App 20170114130 - Rondon; Isaac J. ;   et al.
2017-04-27
Modulation Of Nkg2d
App 20160311906 - LANIER; Lewis L. ;   et al.
2016-10-27
Modulation of NKG2D for prolonging survival of a hematopoietic graft
Grant 9,211,328 - Lanier , et al. December 15, 2
2015-12-15
Cd127 Expression Inversely Correlates With Foxp3 And Suppressive Function Of Cd4+ Tregs
App 20150192582 - Bluestone; Jeffrey A. ;   et al.
2015-07-09
Expansion Of Alloantigen-reactive Regulatory T Cells
App 20150110761 - Tang; Qizhi ;   et al.
2015-04-23
CD127 expression inversely correlates with FoxP3 and suppressive function of CD4.sup.+ Tregs
Grant 9,012,134 - Bluestone , et al. April 21, 2
2015-04-21
Glycosphingolipids For Use In Modulating Immune Responses
App 20140377291 - Fischbach; Michael A. ;   et al.
2014-12-25
Modulation Of Nkg2d
App 20140120082 - LANIER; Lewis L. ;   et al.
2014-05-01
Modulation Of Nkg2d
App 20120064070 - Lanier; Lewis L. ;   et al.
2012-03-15
Regulatory T Cells Suppress Autoimmunity
App 20100310588 - Bluestone; Jeffrey A. ;   et al.
2010-12-09
Use Of Aminopyrimidine Compounds In The Treatment Of Immune Disorders
App 20100210596 - Bluestone; Jeffrey A. ;   et al.
2010-08-19
Regulatory T cells suppress autoimmunity
Grant 7,722,862 - Bluestone , et al. May 25, 2
2010-05-25
Modulation of Nkg2d
App 20080260727 - Lanier; Lewis L. ;   et al.
2008-10-23
Cd127 Expression Inversely Correlates With Foxp3 And Suppressive Function Of Cd4+ Tregs
App 20080131445 - Bluestone; Jeffrey A. ;   et al.
2008-06-05
Regulatory CD8cells induced with anti-CD3 antibody
App 20070190052 - Herold; Kevan ;   et al.
2007-08-16
Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
App 20070190045 - Herold; Kevan ;   et al.
2007-08-16
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
App 20060292142 - Bluestone; Jeffrey A. ;   et al.
2006-12-28
Regulatory T cells suppress autoimmunity
App 20060233751 - Bluestone; Jeffrey A. ;   et al.
2006-10-19
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
App 20060002933 - Bluestone; Jeffrey A. ;   et al.
2006-01-05
Regulatory T cells suppress autoimmunity
App 20050186207 - Bluestone, Jeffrey A. ;   et al.
2005-08-25
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
App 20030108548 - Bluestone, Jeffrey A. ;   et al.
2003-06-12
Surface-bound antigen binding portions of antibodies that bind to CTLA-4 and CD28 and uses therefor
App 20030086932 - Bluestone, Jeffrey A. ;   et al.
2003-05-08
Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
Grant 6,491,916 - Bluestone , et al. December 10, 2
2002-12-10
Mutated class II major histocompatibility proteins
App 20020165149 - Kranz, David M. ;   et al.
2002-11-07
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
Grant 5,885,573 - Bluestone , et al. March 23, 1
1999-03-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed